Release Date: February 20, 2023
Expiration Date: February 20, 2024

Expected time to complete this activity as designed: 15 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

In this newsletter, Dr. Meera Chitlur discusses the role of prophylaxis, individualizing treatment options, and how new therapies impact practice. She explains the remaining challenges of using longer-acting therapies and how individualizing therapy can improve adherence.

Target Audience

This activity is designed for healthcare professionals who treat and manage patients with hemophilia.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

• Review recently approved agents for hemophilia prophylaxis
• Identify patients who may benefit from recently approved agents for hemophilia prophylaxis

Agenda

Selecting Optimal Therapy for Patients with Hemophilia – Meera B. Chitlur, MD

Instructions for Participation and Credit

This activity is eligible for credit through February 20, 2024. After this date, this activity will expire and no further credit will be awarded.

1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Meera B. Chitlur, MD
Professor of Pediatrics
Central Michigan University College of Medicine
and Wayne State University School of Medicine
Detroit, Michigan

Dr. Meera Chitlur received her medical degree at the MES College (Science and Mathematics) in Bangalore, India. She completed her fellowship in Pediatric Hematology/Oncology at Children’s Hospital of Michigan in Detroit. She is currently a Professor of Pediatrics at both Central Michigan University College of Medicine and Wayne State University School of Medicine in Detroit, Michigan.

Dr. Chitlur has been extensively published in numerous medical journals and has been an invited lecturer at many national and international meetings. Dr. Chitlur is a member of the editorial board of Haemophilia and is a reviewer for various other peer reviewed journals. She is a member of a number of committees and review boards for hemophilia and other blood disorders. Dr. Chitlur has been a principal investigator and co-investigator for many current and recently concluded clinical trials.

Accreditation

	CME CREDIT MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
	CPE CREDIT MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-23-001-H01-P. Knowledge-based CPE activity. In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program. International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Disclosures

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.

Faculty Disclosure

Dr. Meera Chitlur has relevant financial relationships related to advisory and/or consulting activities from Agios, Inc. (now Servier Laboratories), Bio Products Laboratory U.S.A., Inc., Genentech-A Member of the Roche Group, National Hemophilia Foundation, Novo Nordisk A/S, and Takeda Pharmaceutical Company Limited. She has received research grant funding from Agios, Inc., Genentech, and Novartis Inc.

All of the relevant financial relationships listed for this individual have been mitigated.

Unapproved Product Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.

Planning Committee

Joan Meyer, RN, MHA, Executive Director, and Andrea Mathis, Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer

Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected].

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from CSL Behring, LLC.

©2023 MediCom Worldwide, Inc., 660 Newtown Yardley Rd, Suite 203 · Newtown, PA 18940, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.